Health Care [ 2/12 ] | Biotechnology [ 3/73 ]
NASDAQ | Common Stock
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States.
The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial.
The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products.
The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.
Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs.
The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa.
It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease.
In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin.
The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014.
InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Sep 29, 25 | -1.20 Decreased by -452.23% | - |
| May 12, 25 | -1.94 Decreased by -979.91% | - |
| Feb 11, 25 | -3.64 Increased by +74.02% | - |
| Nov 12, 24 | -0.22 Decreased by -113.67% | - |
| Sep 27, 24 | -0.22 Increased by +93.31% | - |
| May 14, 24 | -0.18 Increased by +70.13% | -0.18 Increased by +0.44% |
| Feb 13, 24 | -14.03 Decreased by -1.44 K% | -5.50 Decreased by -155.09% |
| Nov 14, 23 | -0.10 Increased by +97.50% | -0.22 Increased by +53.77% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 1.30 M Decreased by -25.67% | -1.79 M Increased by +32.53% | Decreased by -137.07% Increased by +9.24% |
| Mar 31, 25 | 1.27 M Decreased by -19.90% | -2.14 M Increased by +8.34% | Decreased by -168.12% Decreased by -14.42% |
| Dec 31, 24 | 1.11 M Decreased by -32.44% | -2.57 M Decreased by -31.30% | Decreased by -231.63% Decreased by -94.34% |
| Sep 30, 24 | 1.26 M Increased by +3.18% | -1.67 M Increased by +51.33% | Decreased by -132.68% Increased by +52.83% |
| Jun 30, 24 | 1.75 M Decreased by -24.07% | -2.65 M Decreased by -683.12% | Decreased by -151.02% Decreased by -931.39% |
| Mar 31, 24 | 1.59 M Increased by +13.79% | -2.34 M Increased by +13.48% | Decreased by -146.93% Increased by +23.97% |
| Dec 31, 23 | 1.64 M Increased by +160.43% | -1.96 M Increased by +30.60% | Decreased by -119.19% Increased by +73.35% |
| Sep 30, 23 | 1.22 M Increased by +177.74% | -3.44 M Increased by +28.60% | Decreased by -281.29% Increased by +74.29% |